PRLD Healthcare

Prelude Therapeutics Incorporated

$3.78-1.56%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 301.7M USD
Enterprise value: 263.4M USD
Full-time employees: 79

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 0.96 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.96 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #798 of 1,157 healthcare companies (bottom 32%)

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 98% of revenue in 2025.
Prelude Therapeutics paid employees $12M in stock in 2025, 98% of its $12M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Prelude Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 93% of peers, at an operating loss, from a small base ($22M of revenue over 12 months).
Revenue grew faster than 93% of peers, but the business runs at an operating loss (margin -301%).

StockQuotient Score

42/ 100

Oct 5 41 → Nov 4 42 (+1)

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-20.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-24.5%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-11.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield44.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

90/100

Strong

2/3 inputs reported · Partial data

Since last quarter: ▲ Stronger

12-month revenue up 34.1%

Why

Stronger than most peers on:

▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0584 · MAD: 0.0840

Revenue growth73.4%

Yahoo Finance fallback · SEC figure unavailable or out of date · fiscal year to Dec 2025Reported value33% base weight · Z-score 6.91Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

10/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-300.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -25.27Sector median: 0.0706 · MAD: 0.1217

Return on assets-31.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -6.26Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-49.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -5.41Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin100.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-45.2%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Current ratio
▲ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.96

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.00Sector median: 0.6250 · MAD: 0.3380

Current ratio4.07×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.13×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.44Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Prelude Therapeutics

Is Prelude Therapeutics getting weaker?: Its latest SEC filing (Aug 11, 2026) showed no major changes. Its overall score is unchanged at 42/100 since Oct 28, 2026.
How is Prelude Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -20.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -20.1% vs peers 1.5% (weaker than 100% of peers).
Is Prelude Therapeutics growing?: Yes, faster than most of its peers. Growth scores 90/100 against 1,393 healthcare peers. Revenue growth 73.4% vs a peer median of 6.1% (stronger than 93% of peers).Revenue growth 73.4% vs peers 6.1% (stronger than 93% of peers).
How profitable is Prelude Therapeutics?: Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Operating margin -300.6% vs a peer median of 7.1% (weaker than 91% of peers).Operating margin -300.6% vs peers 7.1% (weaker than 91% of peers).
How risky is Prelude Therapeutics?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.07× vs a peer median of 2.59× (stronger than 67% of peers).Current ratio 4.07× vs peers 2.59× (stronger than 67% of peers). Beta 0.96 vs a peer median of 0.63 (weaker than 70% of peers).Beta 0.96 vs peers 0.63 (weaker than 70% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 11, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: Prelude Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	16.7M USD	22.4M USD	+34.1%
Net income (12 months)	−77.8M USD	−60.5M USD	−22.2%
Operating margin	-503.2%	-300.6%	+202.7 pts
Free cash flow (12 months)	−43.8M USD	−33.3M USD	−24.0%
Cash	21.8M USD	26.3M USD	+21.0%
Shares outstanding	79.6M	79.8M	+0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	—	—	—	-1995.9%	-861.3%	▲ >999 pts
Net margin	—	—	—	-1816.8%	-819.6%	▲ 997 pts
Return on assets (ROA)	-36.6%	-52.4%	-43.9%	-72.5%	-70.4%	▲ 2.0 pts
Return on equity (ROE)	-39.1%	-59.1%	-51.4%	-96.7%	-145.0%	▼ 48 pts
Free cash flow margin	—	—	—	-1480.7%	-464.3%	▲ >999 pts
Current ratio	15.37×	9.42×	10.79×	5.30×	1.99×	▼ 62%

PRLD price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 0.96 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.96 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #798 of 1,157 healthcare companies (bottom 32%)

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 98% of revenue in 2025.

Prelude Therapeutics paid employees $12M in stock in 2025, 98% of its $12M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Prelude Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 93% of peers, at an operating loss, from a small base ($22M of revenue over 12 months).

Revenue grew faster than 93% of peers, but the business runs at an operating loss (margin -301%).

Questions investors ask about Prelude Therapeutics

Is Prelude Therapeutics getting weaker?

Its latest SEC filing (Aug 11, 2026) showed no major changes. Its overall score is unchanged at 42/100 since Oct 28, 2026.

How is Prelude Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -20.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -20.1% vs peers 1.5% (weaker than 100% of peers).

Is Prelude Therapeutics growing?

Yes, faster than most of its peers. Growth scores 90/100 against 1,393 healthcare peers. Revenue growth 73.4% vs a peer median of 6.1% (stronger than 93% of peers).Revenue growth 73.4% vs peers 6.1% (stronger than 93% of peers).

How profitable is Prelude Therapeutics?

Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Operating margin -300.6% vs a peer median of 7.1% (weaker than 91% of peers).Operating margin -300.6% vs peers 7.1% (weaker than 91% of peers).

How risky is Prelude Therapeutics?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.07× vs a peer median of 2.59× (stronger than 67% of peers).Current ratio 4.07× vs peers 2.59× (stronger than 67% of peers). Beta 0.96 vs a peer median of 0.63 (weaker than 70% of peers).Beta 0.96 vs peers 0.63 (weaker than 70% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

16.7M USD

22.4M USD

+34.1%

Net income (12 months)

−77.8M USD

−60.5M USD

−22.2%

Operating margin

-503.2%

-300.6%

+202.7 pts

Free cash flow (12 months)

−43.8M USD

−33.3M USD

−24.0%

Cash

21.8M USD

26.3M USD

+21.0%

Shares outstanding

79.6M

79.8M

+0.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

—

-1995.9%

-861.3%

▲ >999 pts

Net margin

—

-1816.8%

-819.6%

▲ 997 pts

Return on assets (ROA)

-36.6%

-52.4%

-43.9%

-72.5%

-70.4%

▲ 2.0 pts

Return on equity (ROE)

-39.1%

-59.1%

-51.4%

-96.7%

-145.0%

▼ 48 pts

Free cash flow margin

—

-1480.7%

-464.3%

▲ >999 pts

Current ratio

15.37×

9.42×

10.79×

5.30×

1.99×

▼ 62%